Effects of buspirone, diazepam, and zolpidem on open field behavior, and brain [3H]muscimol binding after buspirone pretreatment

Pharmacology Biochemistry and Behavior

Volumn 66, Issue 3, 2000, Pages 645-651

  Siemiatkowski, M ^a   Sienkiewicz Jarosz, H ^a,b   Czlonkowska, A I ^b   Bidzinski A ^a   Plaznik A ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; BUSPIRONE; DIAZEPAM; ZOLPIDEM;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; COGNITION; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MOTOR ACTIVITY; NEOPHOBIA; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BRAIN; BUSPIRONE; DIAZEPAM; GABA AGONISTS; GABA MODULATORS; MALE; MOTOR ACTIVITY; MUSCIMOL; PSYCHOMOTOR PERFORMANCE; PYRIDINES; RATS; RATS, WISTAR; SEROTONIN AGONISTS; TRITIUM;

ANIMALIA;

EID: 0033944784     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00200-8     Document Type: Article

References (45)

1. Antelman S.M., DeGiovanni L.A., Kocan D., Perel J.M., Chiodo L.A. Amitryptiline sensitization of a serotonin-mediated behavior depends on the passage of time and not repeated treatment. Life Sci. 33:1983;1727-1730.
2. Antelman S.M., Soares J.C., Gershon S. Time-dependent sensitization - possible implications for clinical psychopharmacology. Behav. Pharmcol. 8:1997;505-514.
3. 3H]muscimol binding in the rat hippocampus. Eur. J. Pharmacol. 353:1998;5-12.
4. Buhot M.C., Naili S. Changes in exploratory activity following stimulation of hippocampal 5-HT1A and 5-HT1B receptors in the rat. Hippocampus. 5:1995;198-208.
5. Burns L.H., Annett L., Kelley A.E., Everitt B.J., Robbins T.W. Effects of lesions to amygdala, ventral subiculum, medial prefrontal cortex, and nucleus accumbens on the reaction to novelty. implication for limbic-striatal interactions Behav. Neurosci. 110:1996;60-73.
6. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacol. Berl. 105:1991;428-432.
7. File S.E., Zangrossi H. Jr., Andrews N. Social interaction and elevated plus maze tests. changes in release and uptake of 5-HT and GABA Neuropharmacol. 32:1993;217-221.
8. Ge J., Barnes N.M., Costall B., Naylor R.J. Effect of aversive stimulation on 5-hydroxytryptamine and dopamine metabolism in the rat brain. Pharmcol. Biochem. Behav. 58:1997;775-783.
9. Goa K.L., Ward A. Buspirone. a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic Drugs. 32:1986;114-129.
10. Gobbi M., Cavanus S., Miari A., Mennini T. Effect of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain. an autoradiographic study Neuropharmacology. 30:1991;313-321.
11. Goldberg A.L., Finnerty R.J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry. 136:1979;1184-1187.
12. Gray J.A. Précis of the neuropsychology of anxiety. an enquiry into the function of the septohippocampal system Behav. Brain Sci. 5:1982;469-534.
13. Gray J.A., McNaughton N. Comparison between the behavioural effects of septal and hippocampal lesions. a review Neurosci. Biobehav. Rev. 7:1983;119-188.
14. Haleem D.J., Batool F. Regionally specific effects of diazepam on brain serotonin metabolism in rats. sustained effects following repeated administration Life Sci. 59:1996;239-246.
15. 1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J. Psychopharmacol. 13:1999;166-170.
16. Kahn R.S., van Praag H.M., Wetzler S., Asnis G., Barr G. Serotonin and anxiety revisited. Biol. Psychiatry. 23:1988;189-208.
17. Kirby L.G., Chou-Green J.M., Davis K., Lucki I. The effects of different stressors on extracellular 5-hyroxytryptamine and 5-hydroxyindoleacetic acid. Brain Res. 760:1997;218-230.
18. Kitchigina V., Vankov A., Harley C., Sara S.J. Novelty-elicited, noradrenaline-dependent enhancement of excitability in the dentate gyrus. Eur. J. Neurosci. 9:1997;41-47.
19. Kuhar M.J., Unnerstall J.R. Receptor autoradiography. Yamamura H.I.et al. Methods in neurotransmitter receptor analysis. 1990;177-218 Raven Press Ltd, New York.
20. López-Rubalcava C., Saldivar A., Fernández-Guasti A. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics. Pharmacol. Biochem. Behav. 43:1992;433-440.
21. Malhotra S., Santosh P.J. Loading dose imipramine-new approach to pharmacotherapy of melancholic depression. J. Psychiatr. Res. 30:1996;51-58.
22. 1A receptor ligands. Eur. J. Pharmacol. 156:1988;375-383.
23. Matsuo M., Kataoka Y., Mataki S., Kato Y., Oi K. Conflict situation increases serotonin release in rat dorsal hippocampus. in vivo study with microdialysis and Vogel test Neurosci. Lett. 215:1996;197-200.
24. Montgomery S.A., Baldwin D., Shah A., Green M., Fineberg N., Montgomery D. Plasma-level response relationships with fluoxetine and zimelidine. Clin. Neuropharmacol. 13(suppl. 1):1990;S71-S75.
25. 1A receptor agonists. (aryl-piperazine derivatives) Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 16:1992;833-845.
26. 3H-zolpidem binding. J. Neural. Transm. 106:1999;355-368.
27. Okazawa H., Yamane F., Blier P., Diksic M. Effects of acute and chronic administration of the serotonin-1A agonist buspirone on serotonin synthesis in the rat brain. J. Neurochem. 72:1999;2022-2031.
28. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A stereotaxic atlas of the rat brain. 1967;Plenum Press, New York.
29. Perrault G., Morel E., Sanger D.J., Zivkovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur. J. Pharmacol. 187:1990;487-494.
30. Plaźnik A. Pharmacology of tolerance to benzodiazepine receptor ligands. Pol. J. Pharmacol. 47:1995;489-499.
31. Pollock B.G., Perel J., Shostak M., Antelman S., Brandom B., Kupfer D.J. Understanding the response lag to tricyclics. I. Application of pulse-loading regimens with intravenous clomipramine. Psychopharmacol. Bull. 22:1986;214-229.
32. Rodgers R.J., Cole J.E. The elevated plus-maze. pharamcology, methodology and ethology Cooper S.J., Hendrie C.A. Ethology and psychopharmacology. 1994;9-44 John Wiley & Sons Ltd, Chichester, UK.
33. Rueter L.E., Jacobs B.L. A microdialysis examination of serotonin release in the rat forebrain induced by behavioral/environmental manipulations. Brain Res. 739:1996;57-69.
34. 1A receptor binding in the rat brain. Eur. Neuropsychopharmacol. 5:1995;49-51.
35. 1A receptors play an important role in modulation of behavior of rats in a two-compartment black and white box. Behav. Pharmacol. 7:1996;788-797.
36. Simon P., Dupuis R., Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions Behav. Brain Res. 61:1994;59-64.
37. Söderpalm B., Engel J.A. Does the pCPA induced anticonflict effect involve activation of the GABAA/Benzodiazepine chloride ionophore receptor complex. J. Neural. Transm. 76:1989;145-153.
38. Abenzodiazepine chloride ionophore receptor complex in the 5, 7-DHT induced anticonflict effect. Life Sci. 49:1991;139-153.
39. A/benzodiazepine chloride ionophore receptor complexes. Life Sci. 51:1992;327-335.
40. Abenzodiazepine receptor complexes. Neuropharmacology. 36:1997;1071-1077.
41. Stefánski R., Patejko W., Kostowski W., Plaźnik A. The comparison of benzodiazepine derivates and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology. 31:1992;1251-1258.
42. 1A receptor agonists. Neuropharmacology. 32:1993;977-985.
43. 3 dopamine receptor-deficient mouse. evidence for reduced anxiety Phys. Behav. 63:1997;137-141.
44. Taylor D.P. Serotonin agents in anxiety. Ann. NY Acad. Sci. 600:1990;547-557.
45. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol. Biochem. Behav. 31:1989;959-962.